Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $1.1 billion.

  • Apellis Pharmaceuticals' Liabilities and Shareholders Equity rose 1739.25% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 billion, marking a year-over-year increase of 424.4%. This contributed to the annual value of $885.1 million for FY2024, which is 1221.22% up from last year.
  • Apellis Pharmaceuticals' Liabilities and Shareholders Equity amounted to $1.1 billion in Q3 2025, which was up 1739.25% from $821.4 million recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Liabilities and Shareholders Equity peaked at $1.1 billion during Q1 2022, and registered a low of $525.7 million during Q3 2021.
  • For the 5-year period, Apellis Pharmaceuticals' Liabilities and Shareholders Equity averaged around $863.7 million, with its median value being $872.9 million (2022).
  • In the last 5 years, Apellis Pharmaceuticals' Liabilities and Shareholders Equity tumbled by 3158.07% in 2021 and then surged by 6604.72% in 2022.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Liabilities and Shareholders Equity stood at $881.8 million in 2021, then fell by 13.78% to $760.2 million in 2022, then increased by 3.75% to $788.7 million in 2023, then increased by 12.21% to $885.1 million in 2024, then increased by 19.62% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $821.4 million for Q2 2025, and $807.3 million during Q1 2025.